Axsome Therapeutics, Inc. (AXSM)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 80M 160M 240M Q3 '24: 104.8M Q4 '24: 118.8M Q1 '25: 121.5M Q2 '25: 150M Q3 '25: 171M Q4 '25: 196M Q1 '26: 191.2M Q2 '26: 218.4M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Gross Profit Quarterly

0 70M 140M 210M Q3 '24: 96.2M Q4 '24: 108.1M Q1 '25: 111.5M Q2 '25: 136.5M Q3 '25: 159M Q4 '25: 183.6M Q1 '26: 176.4M Q2 '26: 204.7M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-75M -50M -25M 0 25M 50M 75M Q3 '24: -62.6M Q4 '24: -72.6M Q1 '25: -57M Q2 '25: -36.7M Q3 '25: -46.1M Q4 '25: -27M Q1 '26: -63.4M Q2 '26: -49.6M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Net Income Quarterly

-90M -60M -30M 0 30M 60M 90M Q3 '24: -64.6M Q4 '24: -74.9M Q1 '25: -59.4M Q2 '25: -48M Q3 '25: -47.2M Q4 '25: -28.6M Q1 '26: -64.5M Q2 '26: -51.3M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Cost of Revenue Quarterly

0 6M 12M 18M Q3 '24: 8.4M Q4 '24: 10.5M Q1 '25: 9.8M Q2 '25: 13.4M Q3 '25: 11.9M Q4 '25: 12.3M Q1 '26: 14.7M Q2 '26: 13.6M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating Cash Flow Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '24: -18.6M Q4 '24: -26.2M Q1 '25: -43.4M Q2 '25: -32.4M Q3 '25: 1M Q4 '25: -18.7M Q1 '26: -20.7M Q2 '26: -33M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Free Cash Flow Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '24: -18.7M Q4 '24: -26.2M Q1 '25: -43.7M Q2 '25: -32.4M Q3 '25: 988K Q4 '25: -18.7M Q1 '26: -20.8M Q2 '26: -33.4M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 20M 40M 60M Q1 '24: 47.4M Q2 '24: 47.6M Q3 '24: 48.1M Q1 '25: 48.9M Q2 '25: 49.4M Q3 '25: 50M Q1 '26: 51.2M Q2 '26: 51.8M Q1 '24 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-7.50 -5.00 -2.50 0.00 2.50 5.00 7.50 Q3 '24: -6.58 Q4 '24: -5.99 Q1 '25: -5.77 Q2 '25: -5.07 Q3 '25: -4.67 Q4 '25: -3.68 Q1 '26: -3.72 Q2 '26: -3.74 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.